Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 471861, 5 pages
http://dx.doi.org/10.1155/2015/471861
Case Report

Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series

1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Received 26 November 2014; Accepted 18 February 2015

Academic Editor: Francesco A. Mauri

Copyright © 2015 Mehmet Asim Bilen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Huggins and C. V. Hodges, “Studies on prostatic cancer: effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate,” Cancer Research, vol. 1, pp. 293–297, 1941. View at Google Scholar
  2. J. S. de Bono, C. J. Logothetis, A. Molina et al., “Abiraterone and increased survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 1995–2005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. I. Scher, K. Fizazi, F. Saad et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. De Bono, S. Oudard, M. Ozguroglu et al., “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial,” The Lancet, vol. 376, pp. 1147–1154, 2010. View at Publisher · View at Google Scholar
  6. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Margel, D. R. Urbach, L. L. Lipscombe et al., “Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes,” Journal of Clinical Oncology, vol. 31, no. 25, pp. 3069–3075, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-X. He, S. M. Tu, M.-H. Lee, and S.-C. J. Yeung, “Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients,” Annals of Oncology, vol. 22, no. 12, Article ID mdr020, pp. 2640–2645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Nobes, S. E. M. Langley, T. Klopper, D. Russell-Jones, and R. W. Laing, “A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy,” BJU International, vol. 109, no. 10, pp. 1495–1502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufí, S. Del Barco, B. Martin-Castilloand, and J. A. Menendez, “Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status,” Cell Cycle, vol. 9, no. 18, pp. 3807–3814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Capodice, P. Gorroochurn, A. S. Cammack et al., “Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial,” Journal of the Society for Integrative Oncology, vol. 7, no. 2, pp. 43–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. L. Bemis, J. L. Capodice, A. G. Anastasiadis, A. E. Katz, and R. Buttyan, “Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression,” Nutrition and Cancer, vol. 52, no. 2, pp. 202–212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Sandur, S. A. Kwang, H. Ichikawa et al., “Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-κB Activation and NF-κB-regulated gene products,” Nutrition and Cancer, vol. 57, no. 1, pp. 78–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. E.-C. Huang, M. F. McEntee, and J. Whelan, “Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer,” Nutrition and Cancer, vol. 64, no. 5, pp. 749–760, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. E.-C. Huang, G. Chen, S. J. Baek et al., “Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer,” Nutrition and Cancer, vol. 63, no. 8, pp. 1287–1296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Cassileth, D. P. Harrington, J. D. Hines et al., “Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia,” Journal of Clinical Oncology, vol. 6, no. 4, pp. 583–587, 1988. View at Google Scholar · View at Scopus
  18. S. M. Tu, Origin of Cancers: Clinical Perspectives and Implications of a Stem-Cell Theory of Cancer, vol. 154 of Cancer Treatment and Research, Springer, New York, NY, USA, 2010, Edited by S. T. Rosen.
  19. S.-M. Tu and S.-H. Lin, “Prostate cancer stem cells,” Clinical Genitourinary Cancer, vol. 10, no. 2, pp. 69–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Moreno-Sánchez, S. Rodríguez-Enríquez, A. Marín-Hernández, and E. Saavedra, “Energy metabolism in tumor cells,” FEBS Journal, vol. 274, no. 6, pp. 1393–1418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Vazquez-Martin, C. Oliveras-Ferraros, S. del Barco, B. Martin-Castillo, and J. A. Menendez, “The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells,” Breast Cancer Research and Treatment, vol. 126, no. 2, pp. 355–364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Oliveras-Ferraros, S. Cufí, A. Vazquez-Martin et al., “Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a,” Cell Cycle, vol. 10, no. 7, pp. 1144–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. I. N. Alimova, B. Liu, Z. Fan et al., “Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro,” Cell Cycle, vol. 8, no. 6, pp. 909–915, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Vazquez-Martin, C. Oliveras-Ferraros, and J. A. Menendez, “The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells,” Cell Cycle, vol. 8, no. 1, pp. 88–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Zhuang and W. K. Keith, “Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1,” Journal of Molecular Signaling, vol. 3, article 18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. I. B. Sahra, K. Laurent, A. Loubat et al., “The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level,” Oncogene, vol. 27, no. 25, pp. 3576–3586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. D. C. Rubinsztein, J. E. Gestwicki, L. O. Murphy, and D. J. Klionsky, “Potential therapeutic applications of autophagy,” Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 304–312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis et al., “Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission,” Cancer Research, vol. 69, pp. 7507–7511, 2009. View at Google Scholar
  30. F. Michor, Y. Iwasa, and M. A. Nowak, “Dynamics of cancer progression,” Nature Reviews Cancer, vol. 4, no. 3, pp. 197–205, 2004. View at Publisher · View at Google Scholar · View at Scopus